Iovance Biotherapeutics is trading 5.3% up now at $10.44 after Barclays maintained its Overweight rating and raised its price target from $13 to $15 on September 17, 2026.
- The analyst action provides the clearest company-specific catalyst for the move.
- Broader support came from a risk-on session, with biotech and major U.S. indexes trading higher.
- The backdrop reinforced momentum in growth-oriented healthcare stocks.